From what we can see, insiders were net sellers in Catalyst Biosciences, Inc.'s (NASDAQ:CBIO ) during the past 12 months. That is, insiders sold the stock in greater numbers than they purchased it.

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2015 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on creating and developing novel medicines ...

Biogen has dumped the dry age-related macular degeneration (AMD) candidate it licensed from Catalyst Biosciences, giving its onetime partner full control of another asset as it weighs up strategic ...

Catalyst Biosciences is targeting the hemophilia space with a strong candidate treating types A and B with inhibitors, and second targeting type B. Current standard of care NovoSeven is administered ...

SOUTH SAN FRANCISCO, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the initiation of dosing in the Company's Phase 1/2 study (MAA-202) of ...